Microbes, intestinal inflammation and probiotics

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 1, 2012, Pages 81-94

  Khan, Mohammad W ^a   Kale, Amod A ^b   Bere, Praveen ^a   Vajjala, Sriharsha ^c   Gounaris, Elias ^a   Pakanati, Krishna Chaitanya ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Necropsy and Histopathology and Clinical Pathology   (India)

^c OSMANIA MEDICAL COLLEGE   (India)

Author keywords

dendritic cells; inflammatory bowel disease; macrophages; probiotics; Toll like receptors

Indexed keywords

ADALIMUMAB; AMFEBUTAMONE; CD14 ANTIGEN; CERTOLIZUMAB PEGOL; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MUCIN 2; MUCIN 3; NERVE CELL ADHESION MOLECULE; PENTOXIFYLLINE; PLACEBO; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

ACUTE PANCREATITIS; CD4+ T LYMPHOCYTE; CELIAC DISEASE; CELL DIFFERENTIATION; COMMENSAL; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; ENTERITIS; EPITHELIUM CELL; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; INNATE IMMUNITY; INTESTINE FLORA; KIDNEY DYSFUNCTION; LACTOBACILLUS ACIDOPHILUS; LYMPHOCYTE PROLIFERATION; MACROPHAGE FUNCTION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PEPTIC ULCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH MUCUS; TREMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; PROBIOTICS;

EID: 83455259767     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.94     Document Type: Review

References (151)

1. Michelsen KS, Arditi M. Toll-like receptors and innate immunity in gut homeostasis and pathology. Curr. Opin. Hematol. 14, 48-54 (2007)
2. Srikanth CV, McCormick BA, Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk. Interdiscip. Perspect. Infect. Dis. 27, 62-68 (2008)
3. Iwasaki A. Mucosal dendritic cells. Annu. Rev. Immunol. 25, 381-418 (2007)
4. Weltzin R, Lucia-Jandris P, Michetti P, et al. Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. J. Cell Biol. 108, 1673-1685 (1989)
5. Neutra MR, Kraehenbuhl JP. The role of transepithelial transport by M cells in microbial invasion and host defense. J. Cell Sci. Suppl. 17, 209-215 (1993)
6. Rimoldi M, Chieppa M, Salucci V, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat. Immunol. 6, 507-514 (2005)
7. Turner JR. Intestinal mucosal barrier function in health and disease. Nat. Rev. 9, 799-809 (2009)
8. Wilson C, Ouellette A, Satchell D, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 286, 113-117 (1999)
9. Ayabe T, Satchell D, Wilson C, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 1, 113-118 (2000)
10. Margolis KG, Stevanovic K, Karamooz N, et al. Enteric neuronal density contributes to the severity of intestinal inflammation. Gastroenterology 141, 588-598 (2011)
11. Charagundla SR, Levine MS, Torigian DA, et al. Diffuse intestinal ganglioneuromatosis mimicking Crohns disease. AJR Am. J. Roentgenol. 182, 1166-1168 (2004)
12. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29, 319-324 (2008)
13. Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J. Exp. Med. 191, 435-444 (2000)
14. Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages: unique effector cells of the innate immune system. Immunol. Rev. 206, 149-159 (2005)
15. Wendelsdorf K, Bassaganya-Riera J, Hontecillas R, et al. Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease. J. Theo. Bio. 4, 1225-1239 (2010)
16. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 308, 1635-1638 (2005)
17. Sartor RB. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res. Immunol. 148, 567-576 (1997)
18. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 357, 13 (2006)
19. Beutler B, Hoebe K, Du X, et al. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. 74, 479-485 (2003)
20. Kumar A, Wu H, Collier-Hyams LS, et al. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J. 26, 4457-4466 (2007)
21. Kelly D, Cambell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5, 104-112 (2004)
22. Silverman N, Paquette N, Immunology. The right resident bugs. Science 319, 734-735 (2008)
23. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 289, 1560-1563 (2000)
24. Stremmel W, Merle U, Zahn A, et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 54, 966-971 (2005)
25. De Hertogh G, Aerssens J, De Hoogt R, et al. Validation of 16S rDNA sequencing in microdissected bowel biopsies from Crohns disease patients to assess bacterial flora diversity. J. Pathol. 209, 532-539 (2006)
26. Sears CL. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin. Microbiol. Rev. 22, 349-369 (2009)
27. Sack RB, Myers LL, Almeido-Hill J, et al. Enterotoxigenic Bacteroides fragilis: epidemiologic studies of its role as a human diarrhoeal pathogen. J. Diarrhoeal Dis. Res. 10, 4-9 (1992)
28. Prindiville TP, Sheikh RA, Cohen SH, et al. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg. Infect. Dis. 6, 171-174 (2000)
29. Toprak NU, Yagci A, Gulloglu BM, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol. Infect. 12, 782-786 (2006)
30. Wu S, Rhee KJ, Zhang M, et al. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J. Cell Sci. 120, 1944-1952 (2007)
31. Halle S, Bumann D, Herbrand H, et al. Solitary intestinal lymphoid tissue provides a productive port of entry for Salmonella enterica serovar Typhimurium. Infect. Immun. 75, 1577-1585 (2007)
32. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307, 254-258 (2005)
33. Vazquez-Torres A, Jones-Carson J, Baumler AJ, et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature 401, 804-808 (1999)
34. Klapproth JM, Sasaki M, Sherman M, et al. Citrobacter rodentium lifA/efa1 is essential for colonic colonization and crypt cell hyperplasia in vivo. Infect. Immun. 73, 1441-1451 (2005)
35. Guttman JA, Samki FN, Li Y, et al. Evidence that tight junctions are disrupted due to intimate bacterial contact and not inflammation during attaching and effacing pathogen infection in vivo. Infect. Immun. 74, 6075-6084 (2006)
36. Satsangi J, Jewell DP, Bell JI. The genetics of inflammatory bowel disease. Gut 40, 572-574 (1997)
37. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39, 596-604 (2007)
38. Hampe J, Franke A, Rosentiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207-211 (2007)
39. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohns disease susceptibility. Nat. Genet. 39, 830-832 (2007)
40. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohns disease. Nat. Genet. 40, 955-962 (2008)
41. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699-5708 (2002)
42. Parrello T, Monteleone G, Cucchiara S, et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohns disease. J. Immunol. 165, 7234-7239 (2000)
43. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003)
44. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456, 264-268 (2008)
45. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533 (2003)
46. Rahman MK, Midtling EH, Svingen PA, et al. The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival. J. Immunol. 184, 7247-7256 (2010)
47. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270, 1203-1207 (1995)
48. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203, 2473-2483 (2006)
49. Kullberg MC, Jankovic D, Feng CG, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203, 2485-2494 (2006)
50. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25, 309-318 (2006)
51. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310-1316 (2006)
52. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434 (2007)
53. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 9, 641-649 (2008)
54. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11, 55-62 (2010)
55. Galluzzi L, Kepp O, Zitvogel L, et al. Bacterial invasion: linking autophagy and innate immunity. Curr. Biol. 20, 106-108 (2010)
56. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohns disease associated ATG16L1 variant. PLoS One 3, 3391 (2008)
57. Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075 (2008)
58. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm. Bowel Dis. 17, 831-848 (2011)
59. Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease-an alliance gone bad. Am. J. Physiol. Gastrointest. Liver Physiol. 295, 1139-1149 (2008)
60. Heazlewood CK, Cook MC, Eri R, et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med. 5, 54 (2008)
61. Hibi T, Ohara M, Kobayashi K, et al. Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut 35, 224-230 (1994)
62. Folwaczny C, Noehl N, Tschop K, et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 113, 101-106 (1997)
63. An G, Wei B, Xia B, et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J. Exp. Med. 204, 1417-1429 (2007)
64. Ho SB, Dvorak LA, Moor RE, et al. Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing. Gastroenterology 131, 1501-1517 (2006)
65. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117-129 (2006)
66. Madsen LK, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in Interleukin-10 gene-deficient mice. Gastroenterology 116(5), 1107-1114 (1999)
67. Madsen LK, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121, 580 (2001)
68. Clayburgh DR, Barrett TA, Tang Y, et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J. Clin. Invest. 115, 2702-2715 (2005)
69. Zolotarevsky Y, Hecht G, Koutsouris A, et al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123, 163-172 (2002)
70. Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 136, 551-563 (2009)
71. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflam. Bowel Dis. 6, 21-33 (2000)
72. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66-75 (2005)
73. Iwasaki A, Kelsall BL. Unique functions of CD11b+, CD8 alpha+, and double-negative Peyers patch dendritic cells. J. Immunol. 166, 4884-4890 (2001)
74. Kuhn, R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993)
75. Kamada N, Hisamatsu T, Okamoto S, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J. Immunol. 175, 6900-6908 (2005)
76. Imai Y, Irimura T. Quantitative measurement of carbohydrate binding activity of mouse macrophage lectin. J. Immunol. Methods 171, 23-31 (1994)
77. Yamamoto K, Ishida C, Shinohara Y, et al. Interaction of immobilized recombinant mouse C-type macrophage lectin with glycopeptides and oligosaccharides. Biochemistry 33, 8159-8166 (1994)
78. Saba K, Denda-Nagai K, Irimura T. A C-type lectin MGL1/CD301a plays an anti-inflammatory role in murine experimental colitis. Am. J. Pathol. 174, 144-152 (2009)
79. Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 35, 669-674 (1994)
80. Meuret GA, Bitzi A, Hammer GB. Macrophage turnover in Crohns disease and ulcerative colitis. Gastroenterology 74, 501-503 (1978)
81. Grimm MC, Pullman WE, Bennett GM, et al. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J. Gastrol. Hepatol. 10, 387-395 (1995)
82. Reinecker HC, Loh EY, Ringler DJ, et al. Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 108, 40-50 (1995)
83. Liu K, Victora GD, Schwickert TA, et al. In vivo analysis of dendritic cell development and homeostasis. Science 324, 392-397 (2009)
84. Schulz O, Jaensson E, Persson EK, et al. Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. J. Exp. Med. 206, 3101-3114 (2009)
85. Krajina T, Leithauser F, Moller P, et al. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur. J. Immunol. 33, 1073-1083 (2003)
86. Duchmann R, Zeitz M. Treg suppress colitis: the role of TGF-b. Gut 55, 604-606 (2006)
87. Darrasse-Jeze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med. 206, 1853-1862 (2009)
88. Siddiqui KR, Laffont S, Powrie F. E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis. Immunity 32, 557-567 (2010)
89. Jung S. Dendritic cells: a question of upbringing. Immunity 32, 502-504 (2010)
90. Varol C, Vallon-Eberhard A, Elinav E, et al. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 31, 502-512 (2009)
91. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129, 50-65 (2005)
92. de Baey A, Mende I, Baretton G, et al. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J. Immunol. 170, 5089-5094 (2003)
93. de Baey A, Mende I, Riethmueller G, et al. Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. Eur. J. Immunol. 31, 1646-1655 (2001)
94. Becker C, Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112, 693-706 (2003)
95. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006)
96. Glas J, Seiderer J, Wetzke M, et al. rs1004819 is the main disease-associated IL23R variant in German Crohns disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One 2, 819 (2007)
97. Mizoguchi A, Ogawa A, Takedatsu H, et al. Dependence of intestinal granuloma formation on unique myeloid DC-like cells. J. Clin. Invest. 117, 605-615 (2007)
98. von Boehmer H. Oral tolerance: is it all retinoic acid? J. Exp. Med. 204, 1737-1739 (2007)
99. Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 202, 1063-1073 (2005)
100. Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface. Immunity 31, 368-376 (2009)
101. Strober W. The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity 31, 377-388 (2009)
102. Barnes, MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity 31, 401-411 (2009)
103. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986)
104. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8, 950-957 (2007)
105. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. 170, 3939-3943 (2003)
106. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25high T cells in inflammatory bowel disease. Gastroenterology 128, 1868-1878 (2005)
107. Makita S, Kanai T, Oshima S, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J. Immunol. 173, 3119-3130 (2004)
108. Defranco AL, Locksley RM, Robertson M. The immune response in infection and inflammatory disease. Immunity 218-219 (2007)
109. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv. Anatom. Pathol. 16, 405-417 (2009)
110. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24, 157-165 (2010)
111. Scribano M, Prantera C, Review article: medical treatment of moderate to severe Crohns disease. Aliment. Pharmacol. Ther. 17, 23-30 (2003)
112. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. BMJ 1, 387-394 (1959)
113. Jewell DP. Corticosteroids for the management of ulcerative colitis and Crohns disease. Gastroenterol. Clin. North Am. 18, 21-34 (1989)
114. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment. Pharmacol. Ther. 10, 81-90 (1996)
115. de Haij S, Daha MR, van Kooten C. Mechanism of steroid action in renal epithelial cells. Kidney Int. 65, 1577-1588 (2004)
116. Di Fazano CS, Messica O, Quennesson S, et al. Two new cases of glucocorticoid-induced pancreatitis. Rev. Rhum. Engl. Ed. 66, 235 (1999)
117. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 225, 92-99 (1998)
118. Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol. Hepatol. 28, 607-614 (2005)
119. Essayan DM. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671-680 (2001)
120. Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-a production from human alveolar macrophages. Am. J. Respir. Crit. Care Med. 159, 508-511 (1999)
121. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6, 903-907 (2006)
122. Pache I, Rogler G, Felley C. TNF-a blockers in inflammatory bowel diseases: practical consensus recommendations and a users guide. Swiss. Med. Wkly 139, 278-287 (2009)
123. Mohamadzadeh M, Duong T, Hoover T, et al. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria. Expert Rev. Vac. 7, 163-174 (2008)
124. Dal Bello F, Hertel C. Oral cavity as natural reservoir for intestinal lactobacilli. Syst. Appl. Microbiol. 29, 69-76 (2006)
125. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 82, 279-289 (2002)
126. Roberts M, Chatfield S, Pickard D, et al. Comparison of abilities of Salmonella enterica Serovar Typhimurium aroA aroD and aroA htrA mutants to act as live vectors. Infect. Immun. 68, 6041-6043 (2000)
127. Stevenson A, Roberts M. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol. Med. Microbiol. 37, 121-128 (2003)
128. Saklani-Jusforgues H, Fontan E, Soussi N, et al. Enteral immunization with attenuated recombinant Listeria monocytogenes as a live vaccine vector: organ-dependent dynamics of CD4 T lymphocytes reactive to a Leishmania major tracer epitope. Infect. Immun. 71, 1083-1090 (2003)
129. Pouwels PH, Leer RJ, Shaw M, et al. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int. J. Food Microbiol. 41, 155-167 (1998)
130. Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Des. 9, 175-191 (2003)
131. Cain AM, Kelly Karpa KD. Clinical utility of probiotics in inflammatory bowel disease. Alt. Ther. 17, 72-79 (2011)
132. Fitzpatrick LR, Hertzog KL, Quatse AL, et al. Effects of the probiotic formulation VSL#3 on colitis in weanling rats. J. Pediatr. Gastroenterol. Nutr. 44, 561-570 (2007)
133. Shibolet O, Karmeli F, Eliakim R, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm. Bowel Dis. 8, 399-406 (2002)
134. Chen ML, Yan BS, Bando Y, et al. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J. Immunol. 180, 7327-7337 (2008)
135. Lammers KM, Vergopoulos A, Babel N, et al. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm. Bowel Dis. 11, 447-454 (2005)
136. Ulisse S, Gionchetti P, DAlo S, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am. J. Gastroenterol. 96, 2691-2699 (2001)
137. Di Giacinto C, Marnaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J. Immunol. 174, 3237-3246 (2005)
138. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100, 1539-1546 (2005)
139. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121, 580-591 (2001)
140. Rachmilewitz D, Katakura K, Karmell F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126, 520-528 (2004)
141. Pagnini C, Saeed R, Bamias G, et al. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc. Natl Acad. Sci. USA 107, 454-459 (2010)
142. Shen B, Brezezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment. Pharmacol. Ther. 22, 721-728 (2005)
143. Eizaguirre I, Urkia NG, Arsensio AB, et al. Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome. J. Pediatr. Surg. 37, 699-702 (2002)
144. Mayer ML, Phillips CM, Stadnyk AW, et al. Synergistic BM-DC activation and immune induction by the oral vaccine vector Streptococcus gordonii and exogenous tumor necrosis factor. Mol. Immunol. 46, 1883-1891 (2009)
145. Mayer ML, Phillips CM, Townsend RA, et al. Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram positive vaccine vector Streptococcus gordonii. Scand. J. Immunol. 69, 351-356 (2009)
146. Mohamadzadeh M, Pfeiler EA, Brown JB, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl Acad. Sci. USA 108, 4623-4630 (2011)
147. Paneths cell. www.britannica.com/EBchecked/ topic/441200/Paneths-cell
148. Nutrition in pediatrics: basic science, clinical applications. http://books.google.com/books?id=wSTIS CdSIosC&pg=PA244&lpg= PA244&dq=p aneth+cell&source=vrt&ots=KZ4tH-wh4 s&sig= mMRz3PETnVY9URDkCDyjoIG kLM8&hl=en&ei=fOR-TeW2BInagQeSyoGgCA&sa= X&oi=book- result&ct=result&resnum=13&ved=0CHk Q6AEwDA#v=onepage&q=paneth%20 cell&f=false
149. VSL#3 A clear answer for symptom relief. www.vsl3.com
150. Products with probiotics: commercial strains sold as probiotics. www.usprobiotics.org/products. asp#commercial
151. Custom Probiotics Inc. Lactobacilli and Bifidobacteria. www.customprobiotics.com/about- probiotics.htm